Develop Market-Entry And Market Expansion Strategies Of Idiopathic Pulmonary Fibrosis Market: Opportunity Analysis and Forecast to 2025
"The
Latest Research Report OpportunityAnalyzer: Idiopathic Pulmonary
Fibrosis - Opportunity Analysis and Forecast to 2025 provides
information on pricing, market analysis, shares, forecast, and
company profiles for key industry participants. -
MarketResearchReports.biz"
About
Idiopathic Pulmonary Fibrosis Market
The IPF therapeutic market is
currently dominated by the only two drugs that have gained marketing
approval for IPF - Roches Esbriet and Boehringer Ingelheims Ofev.
Esbriet was the first drug to gain approval for IPF in 2011 when it
was approved for use in Europe, a full four years before rival Ofev.
However, both gained approval into the largest IPF market of the US
on the same day in October 2014. The top-selling drug in IPF in value
terms is Roches Esbriet, which GlobalData estimates generated
approximately $572m in 2015 from the seven major markets. There is
high R&D activity for the development of new therapies for IPF
and eight promising therapies can potentially enter the market from
2015 to 2025. Numerous novel targets are being studied in the IPF
pipeline, with major pharmaceutical players Roche, Sanofi,
Bristol-Myers Squibb, and Biogen all active in the development
process. Other promising pipeline candidates include FibroGens CTGF
inhibitor, Promediors PTX2 protein, Afferents P2X3 receptor
antagonist, and MediciNovas 5-LO/LT pathway inhibitor. The continued
uptake of Esbriet and Ofev, combined with the introduction of new
novel drugs will shape the future competitive landscape and drive
growth in the IPF market.
Highlights
Get
Sample copy of this Report @
https://www.marketresearchreports.biz/sample/sample/816327
Key Questions Answered
- What was the impact of Esbriet
and Ofev on the IPF market following their FDA approval in 2014 and
what is their future outlook within this market?
- What do physicians think about
Esbriet and Ofev, and how they will be used for IPF during the
forecast period?
- What is the significance of
late-phase pipeline products and how will their launch shape the
future treatment landscape in IPF?
- What are the unmet needs within
the IPF market?
- What are the remaining
opportunities within the IPF market?
Key Findings
- The main drivers of growth for
the IPF market include the increasing uptake of Esbriet and Ofev, the
launch of new novel treatment options during the second half of the
forecast period, and the increasing number of prevalent cases of IPF.
- R&D strategies include the
development of novel therapies, partnerships and acquisitions,
combination of therapies, and targeting niche patient subpopulations.
- The IPF therapeutic market is
characterized by significant unmet needs. The most pressing unmet
need is the development of a product capable of either stabilizing or
reversing progression of IPF. Current therapies Esbriet and Ofev do
not address this need and are only capable of slowing disease
progression.
- With high R&D activity in
the IPF therapeutic market, physicians are looking forward to
pipeline products becoming available, which will enable them to
improve patients treatment.
Scope
- Overview of IPF, including
epidemiology, etiology, pathophysiology, symptoms, diagnosis, and
current treatment options.
- Annualized IPF therapeutic
market revenue, annual cost of therapy and treatment usage pattern
data from 2015 and forecast for ten years to 2025.
- Key topics covered include
strategic competitor assessment, market characterization, unmet
needs, and implications for the IPF therapeutics markets.
- Pipeline analysis: comprehensive
data split across different phases, emerging novel trends under
development, and detailed analysis of mid-stage pipeline drugs.
- Analysis of the current and
future market competition in the global IPF therapeutics markets.
Insightful review of the key industry drivers, restraints and
challenges. Each trend is independently researched to provide
qualitative analysis of its implications.
Reasons to buy
The report will enable you to -
- Develop and design in-licensing
and out-licensing strategies through a review of pipeline products
and technologies, and by identifying the companies with the most
robust pipeline.
- Develop business strategies by
understanding the trends shaping and driving the global IPF
therapeutic markets.
- Drive revenues by understanding
the key trends, innovative products and technologies, market
segments, and companies likely to impact the global IPF therapeutic
markets in the future.
- Formulate effective sales and
marketing strategies by understanding the competitive landscape and
by analyzing the performance of various competitors.
- Identify emerging players with
potentially strong product portfolios and create effective
counter-strategies to gain a competitive advantage.
- Track drug sales in the global
IPF therapeutic markets from 2015-2025.
- Organize sales and marketing
efforts by identifying the market categories and segments that
present maximum opportunities for consolidations, investments and
strategic partnerships.
Send
An Enquiry Request @
https://www.marketresearchreports.biz/sample/enquiry/816327
Table of Contents
1 Table of Contents 10
1.1 List of Tables 15
1.2 List of Figures 18
2 Introduction 19
2.1 Catalyst 19
2.2 Related Reports 20
3 Disease Overview 21
3.1 Etiology and Pathophysiology
24
3.1.1 Etiology 24
3.1.2 Pathophysiology 25
3.2 Classification or Staging
System 28
3.3 Prognosis 31
3.4 Quality of Life 31
3.5 Symptoms 32
4 Epidemiology 34
4.1 Disease Background 34
4.2 Risk Factors and Comorbidities
34
4.3 Global Trends 36
4.3.1 Incidence 36
4.3.2 Prevalence 37
4.4 Forecast Methodology 39
4.4.1 Sources Used 39
4.4.2 Forecast Assumptions and
Methods 44
4.4.3 Sources Not Used 51
4.5 Epidemiological Forecast for
IPF (2015-2025) 52
4.5.1 Diagnosed Incident Cases 52
4.5.2 Diagnosed Prevalent Cases 60
4.5.3 IPF Mortality 67
4.6 Discussion 72
4.6.1 Epidemiological Forecast
Insight 72
4.6.2 Limitations of the Analysis
73
4.6.3 Strengths of the Analysis 74
5 Current Treatment Options 75
5.1 Overview 75
5.2 Product Profiles - Major
Brands 77
5.2.1 Esbriet (Pirfenidone) 77
5.2.2 Ofev (Nintedanib) 82
5.2.3 Fluimucil (N-acetylcysteine)
87
6 Unmet Needs Assessment and
Opportunity Analysis 91
6.1 Overview 91
6.2 Lack of an Efficacious Drug 92
6.2.1 Overview 92
6.2.2 Gap Analysis 93
6.2.3 Opportunity 93
6.3 Patient Access to Costly
Treatments 93
6.3.1 Overview 93
6.3.2 Gap Analysis 94
6.3.3 Opportunity 95
6.4 Early and Prompt Diagnosis 95
6.4.1 Overview 95
6.4.2 Gap Analysis 96
6.4.3 Opportunity 97
6.5 Unrecognized Disease 97
6.5.1 Overview 97
6.5.2 Gap Analysis 98
6.5.3 Opportunity 98
6.6 Lack of Treatment Options for
Patients with Late Stage Disease 99
6.6.1 Overview 99
6.6.2 Gap Analysis 100
6.6.3 Opportunity 100
6.7 Improvement in Patient Quality
Of Life 100
6.7.1 Overview 100
6.7.2 Gap Analysis 101
6.7.3 Opportunity 101
6.8 Improved Side Effects and
Dosing Regimen 101
6.8.1 Overview 101
6.8.2 Gap Analysis 102
6.8.3 Opportunity 102
7 R&D Strategies 103
7.1 Overview 103
7.1.1 Drug Development Strategy:
Combination Therapy 103
7.1.2 Improving Understanding of
Disease Mechanism 104
7.1.3 Licensing and Alliances 105
7.1.4 Niche Patient Subgroups 105
7.2 Clinical Trial Design 106
7.2.1 Selection of Appropriate
Clinical Trial Endpoints 106
About
us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
Mr.
Nachiket
State
Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
Comments
Post a Comment